middl
east
respiratori
syndromecoronaviru
merscov
first
identifi
saudi
arabia
emerg
zoonot
pathogen
caus
sever
acut
respiratori
ill
human
high
fatal
rate
sinc
emerg
merscov
continu
spread
countri
outsid
arabian
peninsula
give
rise
sporad
human
infect
follow
entri
infect
individu
countri
precipit
outbreak
similar
one
occur
south
korea
current
therapeut
merscov
infect
primarili
adapt
previou
drug
use
treatment
sever
acut
respiratori
syndrom
search
new
potenti
drug
candid
screen
librari
compos
clinic
approv
drug
pharmacolog
activ
compound
drug
saracatinib
potent
inhibitor
srcfamili
tyrosin
kinas
sfk
identifi
inhibitor
merscov
replic
vitro
result
suggest
saracatinib
potent
inhibit
merscov
earli
stage
viral
life
cycl
cell
possibl
suppress
sfk
signal
pathway
furthermor
saracatinib
exhibit
synergist
effect
gemcitabin
anticanc
drug
antivir
activ
sever
rna
virus
data
indic
saracatinib
alon
combin
gemcitabin
provid
new
therapeut
option
treatment
merscov
infect
eastern
countri
associ
humantohuman
spread
typic
start
healthcar
set
result
sporad
outbreak
clinic
featur
merscov
infect
human
rang
asymptomat
sever
lower
respiratori
tract
infect
potenti
develop
acut
respiratori
distress
syndrom
septic
shock
multiorgan
failur
result
death
due
high
morbid
mortal
rate
therapeut
option
merscov
immedi
adapt
previou
report
sever
acut
respiratori
syndrom
sar
therapi
includ
use
broadspectrum
antibiot
corticosteroid
interferon
ribavirin
lopinavirritonavir
andor
mycophenol
mofetil
none
effect
random
control
trial
therefor
rapid
discoveri
effect
prophylact
therapeut
measur
prevent
treat
mer
urgent
need
repurpos
clinic
valid
product
valuabl
approach
drug
discoveri
potenti
greatli
reduc
time
cost
associ
develop
licensur
de
novo
therapeut
prompt
respons
avail
therapeut
option
especi
critic
control
spread
highli
infecti
pathogen
merscov
along
line
sever
food
drug
administr
fda
approv
compound
report
inhibit
merscov
replic
cell
cultur
sinc
emerg
search
addit
merscov
inhibitor
conduct
screen
approv
drug
biolog
activ
molecul
use
cytopathiceffect
cpe
base
highthroughput
screen
ht
assay
result
identifi
saracatinib
potent
inhibitor
srcfamili
tyrosin
kinas
sfk
inhibitor
merscov
well
member
coronavirida
famili
evalu
antivir
activ
saracatinib
found
suppress
earli
stage
merscov
life
cycl
cell
possibl
suppress
sfk
signal
pathway
furthermor
assess
combin
effect
saracatinib
anoth
chemotherapeut
agent
gemcitabin
cell
enhanc
effect
lower
toxic
observ
combin
two
drug
data
present
studi
suggest
saracatinib
alon
combin
agent
provid
new
therapeut
option
treatment
merscov
infect
emerg
reemerg
infecti
diseas
repres
signific
threat
global
public
health
socioeconom
stabil
wit
numer
outbreak
past
decad
middl
east
respiratori
syndromecoronaviru
merscov
first
identifi
saudi
arabia
second
zoonot
introduct
highli
pathogen
coronaviru
human
popul
within
decad
sinc
emerg
merscov
continu
spread
countri
outsid
arabian
peninsula
caus
epidem
high
fatal
rate
merscov
member
genu
betacoronaviru
famili
coronavirida
primari
transmiss
merscov
suspect
occur
close
contact
human
infect
anim
reservoir
dromedari
camel
infect
occur
middl
atcc
betacoronaviru
strain
atcc
purchas
atcc
amplifi
cell
felin
infecti
periton
viru
fipv
atcc
purchas
atcc
amplifi
crfk
cell
saracatinib
puriti
purchas
selleckchem
houston
tx
usa
gemcitabin
hydrochlorid
puriti
obtain
sigmaaldrich
st
loui
mo
usa
analysi
compound
prepar
dimethyl
sulfoxid
dmso
sigmaaldrich
rabbit
antimerscov
nucleocapsid
n
antibodi
purchas
sino
biolog
inc
cat
beij
china
antibodi
fyn
lyn
src
ye
purchas
cell
signal
technolog
danver
usa
load
control
monoclon
antibodi
purchas
sigmaaldrich
horseradish
peroxidas
hrp
conjug
goat
antirabbit
antimous
secondari
antibodi
purchas
thermo
fisher
scientif
waltham
usa
follow
compound
librari
use
studi
collect
microsourc
discoveri
system
gaylordsvil
ct
usa
compris
fdaapprov
drug
drug
substanc
approv
use
europ
asia
ii
prestwick
chemic
librari
prestwick
chemic
san
diego
ca
usa
consist
mostli
approv
drug
fda
european
medicin
agenc
agenc
iii
tocriscreen
librari
tocri
bioscienc
bristol
unit
kingdom
consist
fdaapprov
compound
iv
inhous
librari
compris
biolog
activ
compound
includ
known
drug
experiment
bioactiv
compound
pure
natur
product
deposit
korea
chemic
bank
krict
daejeon
republ
korea
librari
compound
dissolv
dmso
cpeinhibit
assay
use
screen
inhibitor
merscov
previous
describ
briefli
cell
seed
plate
densiti
cellswel
overnight
incub
cell
c
equal
volum
merscov
inoculum
multipl
infect
moi
compound
dilut
final
concentr
ad
incub
c
co
incub
three
day
day
three
postinfect
pi
cell
viabil
measur
use
celltit
aq
ueou
one
solut
cell
prolifer
assay
mt
promega
madison
wi
usa
accord
manufactur
instruct
absorb
nm
measur
use
synergi
tm
multimod
micropl
reader
biotek
winooski
vt
usa
percent
inhibit
calcul
use
valu
maximum
infect
deriv
infect
cultur
treat
dmso
viru
control
inhibit
background
deriv
mockinfect
treat
dmso
cell
control
inhibit
refer
use
formula
sampl
viru
control
cell
control
viru
control
statist
valid
merscov
primari
screen
system
determin
calcul
zfactor
use
valu
deriv
viru
control
cell
control
well
primari
screen
zfactor
coeffici
variat
cv
among
control
use
valid
result
assay
antivir
activ
hit
compound
determin
doserespons
curv
drc
effect
concentr
ec
compoundspecif
toxic
cytotox
concentr
cc
calcul
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
use
nonlinear
regress
formula
log
inhibitor
vs
responsevari
respons
four
paramet
model
one
day
prior
infect
cell
cellswel
seed
tissu
cultur
plate
next
day
cell
infect
merscov
moi
h
c
addit
timeofaddit
experi
combin
temperatureshift
assay
perform
briefli
cell
inocul
merscov
c
h
attachmentbind
unadsorb
viru
remov
wash
three
time
icecold
pb
replenish
fresh
cultur
medium
subsequ
plate
shift
c
allow
synchron
entri
infect
saracatinib
treat
c
incub
ad
specif
time
point
c
incub
antivir
activ
compound
analyz
h
pi
measur
number
infecti
viral
particl
intracellular
viral
rna
express
level
use
plaqu
assay
rtqpcr
respect
infecti
merscov
titer
determin
plaqu
assay
describ
previous
briefli
vero
cell
seed
plate
cellswel
cultur
overnight
c
co
incub
cell
inocul
tenfold
serial
dilut
cell
cultur
supernat
h
c
adsorpt
cell
wash
pb
overlaid
dmem
contain
agaros
mp
biomed
solon
oh
usa
fb
three
day
incub
plaqu
visual
stain
neutral
red
sigmaaldrich
total
cellular
rna
purifi
use
rneasi
mini
kit
qiagen
valencia
ca
usa
accord
manufactur
instruct
rtqpcr
perform
use
superscript
iii
onestep
rtqpcr
system
platinum
taq
polymeras
thermo
fisher
scientif
primersprob
set
target
open
read
frame
upe
gene
tabl
quantstudio
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
describ
previous
rel
viral
rna
express
level
fold
chang
calcul
method
dehydrogenas
gapdh
use
endogen
control
two
biolog
replic
technic
duplic
use
quantif
cell
infect
merscov
moi
mockinfect
treat
tenfold
serial
dilut
compound
h
pi
cell
wash
pb
lyse
use
cell
lysi
buffer
thermo
fisher
scientif
contain
proteas
inhibitor
cocktail
pierc
rockford
il
usa
cell
lysat
clarifi
centrifug
total
protein
content
determin
bradford
protein
assay
biorad
hercul
ca
usa
equal
amount
protein
subject
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
electrotransf
polyvinyliden
fluorid
pvdf
membran
immobilon
p
pvdf
membran
merck
millipor
counti
cork
ireland
membran
block
trisbuff
salinet
tween
sigmaaldrich
contain
skim
milk
h
room
temperatur
merscov
n
protein
detect
use
primari
antibodi
specif
viral
n
protein
follow
horseradish
peroxidas
hrp
conjug
goat
antirabbit
secondari
antibodi
cellular
protein
load
control
detect
primari
antibodi
hrpconjug
goat
antimous
secondari
antibodi
addit
chemiluminesc
hrp
substrat
supersign
west
pico
chemiluminesc
substrat
pierc
imag
obtain
use
luminesc
imag
analyz
fujifilm
tokyo
japan
cell
transfect
pool
two
three
specif
small
interf
rna
sirna
human
fyn
geneid
lyn
gene
id
src
geneid
ye
geneid
sirna
univers
neg
control
bioneer
daejeon
republ
korea
final
concentr
nm
use
lipofectamin
rnaimax
transfect
reagent
thermo
fisher
scientif
accord
manufactur
instruct
effici
knockdown
target
monitor
western
blot
analysi
h
sirna
transfect
evalu
drug
combin
effect
vitro
saracatinib
combin
gemcitabin
differ
concentr
seriallydilut
singl
compound
combin
dose
matric
merscov
inhibit
evalu
cpeinhibit
assay
describ
combin
indic
ci
calcul
use
compusyn
softwar
combosyn
inc
paramu
nj
usa
accord
loew
addit
model
describ
previous
order
identifi
compound
antivir
activ
merscov
employ
cellbas
antivir
screen
assay
base
protect
cell
viral
cpe
primari
screen
clinic
approv
drug
pharmacolog
activ
compound
final
concentr
identifi
compound
merscov
antivir
activ
cutoff
inhibit
yield
hit
rate
figur
averag
z
score
primari
screen
indic
assay
robust
reliabl
detect
potenti
merscov
inhibitor
figur
confirm
antivir
activ
select
compound
merscov
infect
perform
test
complet
doserespons
analys
rang
ec
cc
valu
determin
use
method
determin
hit
compound
primarili
classifi
antiprotozo
anticanc
antipsychot
activ
merscov
micromolar
ec
valu
rang
tabl
among
identifi
hit
saracatinib
figur
particularli
promis
exhibit
promin
antivir
activ
estim
ec
cc
result
select
index
si
approxim
figur
prior
proceed
test
whether
saracatinib
display
antivir
activ
differ
strain
merscov
cell
infect
recombin
merscov
rmerscov
deriv
strain
cell
cultur
adapt
variant
deriv
viru
result
saracatinib
exhibit
ec
rmerscov
respect
suggest
broadspectrum
antimerscov
activ
drug
figur
moreov
saracatinib
show
broadantivir
activ
human
coronavirus
ec
respect
felin
infecti
periton
viru
fipv
ec
within
nontox
rang
concentr
tabl
determin
whether
saracatinib
directli
inhibit
merscov
infect
first
assess
effect
saracatinib
product
merscov
infecti
progeni
viru
number
viral
titer
measur
cell
cultur
supernat
saracatinibtr
cell
follow
infect
merscov
plaqu
assay
shown
figur
dosedepend
reduct
infecti
merscov
titer
exceed
observ
close
saracatinib
compar
untreat
control
treatment
saracatinib
result
margin
reduct
viral
titer
next
assess
impact
express
viral
n
protein
synthesi
merscov
rna
western
blot
analysi
rtqpcr
respect
infect
cell
merscov
moi
harvest
total
cell
lysat
h
pi
western
blot
analysi
show
nearli
complet
abrog
viral
n
protein
express
infect
cell
treat
saracatinib
wherea
treatment
saracatinib
lower
affect
express
viral
n
protein
level
figur
consist
reduct
viral
titer
dosedepend
reduct
intracellular
viral
genom
figur
viral
mrna
upe
figur
observ
infectedcel
treat
saracatinib
compar
untreat
control
treatment
saracatinib
result
near
complet
inhibit
intracellular
viral
genom
mrna
synthes
togeth
data
confirm
vitro
antimerscov
activ
saracatinib
reduc
product
progeni
viru
well
express
viral
rna
protein
level
micromolar
rang
determin
whether
saracatinib
directli
inhibit
merscov
infect
first
assess
effect
saracatinib
product
merscov
infecti
progeni
viru
number
viral
titer
measur
cell
cultur
supernat
saracatinibtr
cell
follow
infect
merscov
plaqu
assay
shown
figur
dosedepend
reduct
infecti
merscov
titer
exceed
observ
close
saracatinib
compar
untreat
control
treatment
saracatinib
result
margin
reduct
viral
titer
next
assess
impact
express
viral
n
protein
synthesi
merscov
rna
western
blot
analysi
rtqpcr
respect
infect
cell
merscov
moi
harvest
total
cell
lysat
h
pi
western
blot
analysi
show
nearli
complet
abrog
viral
n
protein
express
infect
cell
treat
saracatinib
wherea
treatment
saracatinib
lower
affect
express
viral
n
protein
level
figur
consist
reduct
viral
titer
dosedepend
reduct
intracellular
viral
genom
figur
viral
mrna
upe
figur
observ
infectedcel
treat
saracatinib
compar
untreat
control
treatment
saracatinib
result
near
complet
inhibit
intracellular
viral
genom
mrna
synthes
togeth
data
confirm
vitro
antimerscov
activ
saracatinib
reduc
product
progeni
viru
well
express
viral
rna
protein
level
micromolar
rang
c
quantif
intracellular
merscov
rna
rtqpcr
assay
total
rna
isol
lysat
infect
cell
quantif
intracellular
merscov
rna
level
upe
result
normal
gapdh
mrna
data
repres
mean
least
two
independ
experi
perform
duplic
signific
differ
indic
p
p
p
p
investig
step
merscov
life
cycl
affect
saracatinib
timeofadditionremov
experi
perform
saracatinib
ad
cell
either
h
prior
pretreat
cotreat
h
h
infect
posttreat
merscov
figur
h
pi
amount
releas
viru
particl
cell
cultur
supernat
determin
plaqu
assay
shown
figur
saracatinib
treatment
prior
infect
result
similar
viral
titer
compar
untreat
cell
indic
blockag
cellular
receptor
modeof
action
clarifi
possibl
saracatinib
interact
directli
viru
particl
cellular
receptor
viru
attach
perform
c
presenc
absenc
saracatinib
h
adsorpt
cell
wash
replenish
fresh
media
follow
incub
c
allow
viru
intern
viru
titer
cell
cultur
supernat
saracatinibtr
cell
incub
c
similar
untreat
cell
suggest
saracatinib
interact
either
viru
particl
cellular
receptor
contrast
addit
drug
viru
infect
c
result
mark
reduct
viral
titer
figur
co
p
well
signific
decreas
intracellular
viral
genom
rna
mrna
express
figur
moreov
reduct
merscov
titer
becam
pronounc
saracatinib
ad
h
viru
inocul
indic
drug
interf
earli
stage
viral
replic
intern
figur
post
antivir
activ
becam
less
effect
saracatinib
ad
h
postinocul
figur
post
inhibitori
effect
promin
accumul
intracellular
merscov
rna
synthes
intracellular
viral
genom
rna
mrna
sever
affect
upon
treatment
drug
ad
h
post
viru
inocul
figur
precis
understand
time
window
saracatinibmedi
inhibit
merscov
replic
saracatinib
ad
infect
cell
differ
time
point
infect
remain
present
sampl
collect
figur
h
pi
infecti
particl
intracellular
merscov
genom
rna
mrna
quantifi
mention
shown
figur
f
saracatinib
ad
within
first
h
pi
result
signific
reduct
infecti
viru
titer
near
complet
inhibit
viral
genom
rna
mrna
synthes
togeth
data
suggest
saracatinib
potent
inhibit
earli
stage
merscov
life
cycl
intern
previous
mention
saracatinib
signific
inhibitori
activ
sever
member
sfk
well
abelson
abl
kinas
next
investig
role
member
sfk
fyn
lyn
src
ye
merscov
replic
express
cell
use
rnaibas
approach
express
kinas
knock
cell
prior
merscov
infect
signific
knockdown
target
kinas
achiev
cell
confirm
western
blot
analys
h
postsirna
transfect
figur
sirnatransfect
cell
infect
merscov
moi
h
pi
observ
signific
reduct
viru
titer
cell
knock
fyn
lyn
kinas
sirna
figur
contrast
signific
inhibit
merscov
replic
observ
yesknock
cell
extent
src
kinas
knock
effici
enough
determin
role
kinas
merscov
replic
studi
nevertheless
data
suggest
express
fyn
lyn
kinas
may
necessari
effici
merscov
replic
viru
titrat
use
plaqu
assay
e
f
total
rna
isol
infect
lysat
use
analys
intracellular
merscov
genom
rna
mrna
upe
qrtqpcr
data
repres
mean
sd
two
independ
experi
perform
duplic
signific
differ
indic
p
p
p
p
previous
mention
saracatinib
signific
inhibitori
activ
sever
member
sfk
well
abelson
abl
kinas
next
investig
role
member
sfk
fyn
lyn
src
ye
merscov
replic
express
cell
use
rnaibas
approach
express
kinas
knock
cell
prior
merscov
infect
signific
knockdown
target
kinas
achiev
cell
confirm
western
blot
analys
h
postsirna
transfect
figur
sirnatransfect
cell
infect
merscov
moi
h
pi
observ
signific
reduct
viru
titer
cell
knock
fyn
lyn
kinas
sirna
figur
contrast
signific
inhibit
merscov
replic
observ
yesknock
cell
extent
src
kinas
knock
effici
enough
determin
role
kinas
merscov
replic
studi
nevertheless
data
suggest
express
fyn
lyn
kinas
may
necessari
effici
merscov
replic
final
explor
possibl
use
saracatinib
combinatori
therapi
clinic
avail
drug
gemcitabin
deoxycytidin
analog
commonli
use
treatment
cancer
figur
recent
sever
studi
shown
broadspectrum
antivir
effect
enterovirus
highli
pathogen
coronavirus
includ
merscov
sarscov
prior
analyz
efficaci
combin
confirm
antimerscov
potenti
gemcitabin
cellbas
assay
briefli
gemcitabin
treatment
show
convinc
dosedepend
antivir
effect
cell
ec
noncytotox
concentr
rang
figur
subsequ
treatment
higher
dose
gemcitabin
complet
abolish
product
infecti
merscov
particl
well
express
viral
n
protein
express
assess
plaqu
assay
western
blot
analysi
respect
figur
final
explor
possibl
use
saracatinib
combinatori
therapi
clinic
avail
drug
gemcitabin
deoxycytidin
analog
commonli
use
treatment
cancer
figur
recent
sever
studi
shown
broadspectrum
antivir
effect
enterovirus
highli
pathogen
coronavirus
includ
merscov
sarscov
prior
analyz
efficaci
combin
confirm
antimerscov
potenti
gemcitabin
cellbas
assay
briefli
gemcitabin
treatment
show
convinc
dosedepend
antivir
effect
cell
noncytotox
concentr
rang
figur
subsequ
treatment
higher
dose
gemcitabin
complet
abolish
product
infecti
merscov
particl
well
express
viral
n
protein
express
assess
plaqu
assay
western
blot
analysi
respect
figur
next
investig
effect
saracatinib
combin
gemcitabin
merscov
infect
cell
simultan
treat
dose
rang
ec
saracatinib
gemcitabin
combin
antivir
effect
assess
use
colorimetr
cell
viabil
assay
figur
combin
index
ci
calcul
accord
method
chou
et
al
analyz
use
compusyn
softwar
combin
saracatinib
gemcitabin
show
consider
synergist
antivir
effect
ci
valu
ci
indic
synerg
addit
effect
antagon
respect
tabl
moreov
noteworthi
combin
treatment
show
differenti
cytotox
compar
saracatinib
alon
importantli
combin
saracatinib
gemcitabin
show
less
cytotox
gemcitabin
alon
cell
indic
suitabl
use
lowdos
combin
therapi
individu
drug
use
alon
figur
togeth
result
suggest
saracatinib
use
effect
combin
gemcitabin
merscov
infect
next
investig
effect
saracatinib
combin
gemcitabin
merscov
infect
cell
simultan
treat
dose
rang
saracatinib
gemcitabin
combin
antivir
effect
assess
use
colorimetr
cell
viabil
assay
figur
combin
index
ci
calcul
accord
method
chou
et
al
analyz
use
compusyn
softwar
combin
saracatinib
gemcitabin
show
consider
synergist
antivir
effect
ci
valu
ci
indic
synerg
addit
effect
antagon
respect
tabl
moreov
noteworthi
combin
treatment
show
differenti
cytotox
compar
saracatinib
alon
importantli
combin
saracatinib
gemcitabin
show
less
cytotox
gemcitabin
alon
cell
indic
suitabl
use
lowdos
combin
therapi
individu
drug
use
alon
figur
togeth
result
suggest
saracatinib
use
effect
combin
gemcitabin
merscov
infect
base
rang
ci
valu
describ
previous
studi
describ
antivir
activ
saracatinib
merscov
infect
cell
saracatinib
develop
treatment
tumor
malign
identifi
screen
antimerscov
activ
approv
drug
biolog
activ
molecul
use
cpebas
ht
assay
primari
screen
identifi
sever
drug
includ
chloroquin
amodiaquin
chloropromazin
analog
previous
report
inhibitor
merscov
group
indic
valid
screen
result
addit
found
two
neurotransmitt
inhibitor
dosulepin
hydroxyzin
pamoat
differ
chemic
core
structur
previous
report
inhibit
replic
merscov
vitro
micromolar
concentr
moreov
protein
kinas
c
inhibitor
sotrastaurin
undergo
clinic
trial
prevent
organ
transplant
reject
psoriasi
treatment
also
block
merscov
infect
cell
ec
approxim
low
cellular
toxic
cc
howev
si
molecul
limit
compar
saracatinib
select
studi
saracatinib
oral
avail
small
molecul
potent
sfk
member
abl
kinas
block
atpbind
site
sfk
relat
kinas
play
central
role
regul
multipl
signal
transduct
pathway
involv
gene
transcript
cytoskeleton
organ
cell
prolifer
essenti
viral
replic
sever
research
group
demonstr
sfk
associ
divers
aspect
viral
infect
includ
induct
antivir
immun
respons
well
facilit
viral
entri
coxsackieviru
influenza
viru
ebola
viru
kaposi
sarcomaassoci
herpesviru
rna
replic
hepat
c
viru
west
nile
viru
assembl
regul
multipl
stage
human
immunodefici
replic
data
show
saracatinib
inhibit
merscov
replic
reduc
viru
titer
micromolar
rang
product
infecti
viru
particl
well
synthes
viral
genom
rna
mrna
sever
affect
saracatinib
ad
cell
left
first
h
viru
infect
antivir
effect
significantli
reduc
drug
ad
h
infect
suggest
drug
inhibit
earli
stage
merscov
life
cycl
subsequ
aim
identifi
target
saracatinib
involv
merscov
infect
rnaideplet
fyn
lyn
src
ye
express
cell
data
show
knockdown
fyn
lyn
result
signific
reduct
merscov
titer
although
effect
less
sever
compar
saracatinib
treatment
differ
could
explain
fact
saracatinib
pansfk
select
agent
potent
inhibit
sever
member
sfk
well
nonreceptor
tyrosin
kinas
abl
suggest
multipl
kinas
might
involv
merscov
infect
addit
ubiquit
express
member
sfk
lead
high
level
function
redund
remain
sfk
member
compens
function
inact
regrett
could
definit
determin
whether
deplet
src
kinas
activ
alon
combin
member
sfk
detriment
effect
merscov
replic
due
experiment
limit
use
sirnabas
knockdown
assay
particularli
import
sinc
previou
studi
demonstr
multipl
member
sfk
especi
src
fyn
ye
kinas
often
conjunct
abl
kinas
play
import
role
life
cycl
variou
virus
recent
coleman
et
al
indic
imatinib
target
requir
effici
sarscov
merscov
replic
vitro
follow
studi
sisk
et
al
demonstr
abl
kinas
activ
associ
pathway
involv
coronaviru
fusion
step
endosom
membran
well
cellcel
fusion
occur
late
infect
thu
specul
antimerscov
activ
saracatinib
mediat
similarli
via
inhibit
multipl
member
sfk
includ
fynlyn
togeth
kinas
exact
mechan
action
multipl
member
sfk
togeth
kinas
associ
pathway
involv
merscov
replic
current
investig
laboratori
due
central
function
individu
sfk
mani
signal
pathway
egf
receptor
egfr
rasrafmek
jakstat
pathway
involv
cell
metabol
possibl
mechan
fynlyn
member
sfk
may
affect
infecti
cycl
merscov
coronavirus
along
line
previou
studi
kinom
analysi
merscov
infect
indic
erkmapk
intermedi
particular
play
import
role
cours
infect
similarli
close
relat
murin
coronaviru
mous
hepat
viru
mhv
inhibitori
effect
phosphoryl
substrat
specif
inhibitor
result
strong
suppress
mhv
propag
step
viral
rna
synthesi
cultur
cell
find
infer
suppress
sfk
result
neg
regul
downstream
signal
respons
erkmapk
pathway
turn
advers
effect
coronaviru
replic
howev
effect
saracatinib
variou
signal
pathway
remain
elucid
sever
fdaapprov
tyrosin
kinas
inhibitor
activ
use
clinic
clinic
trial
cancer
treatment
howev
increas
evid
shown
cell
acquir
resist
agent
activ
modifi
signal
pathway
replac
lack
signal
target
therapi
overcom
limit
evalu
combin
effect
saracatinib
anoth
chemotherapeut
agent
gemcitabin
differ
mechan
action
compens
drug
resist
may
aris
gemcitabin
fdaapprov
anticanc
drug
deoxycytidin
analog
interfer
normal
dnarna
synthesi
inhibit
ribonucleosid
reductas
previou
studi
shown
gemcitabin
exhibit
broad
spectrum
antivir
effect
sever
rna
virus
includ
influenza
viru
enterovirus
coronavirus
cotreat
saracatinib
gemcitabin
show
synergist
antivir
effect
minim
cytotox
effect
support
idea
use
combin
therapi
potenti
efficaci
nontox
concentr
well
overcom
drug
resist
issu
summari
studi
suggest
saracatinib
show
antivir
activ
earli
stage
merscov
life
cycl
intern
cell
possibl
mechan
suppress
sfk
signal
pathway
addit
identifi
fyn
lyn
kinas
addit
host
factor
involv
merscov
infect
thu
result
support
view
host
kinas
sfk
play
import
role
coronaviru
infect
similarli
fdaapprov
kinas
inhibitor
test
antivir
activ
human
coronavirus
use
tool
identifi
novel
host
kinas
involv
viru
replic
moreov
vitro
synergist
antivir
effect
saracatinib
combin
gemcitabin
merscov
infect
suggest
lower
therapeut
dosag
may
use
prevent
toxic
side
effect
drug
may
therapeut
concentr
taken
togeth
find
provid
insight
potenti
use
clinic
valid
sfk
kinas
inhibitor
futur
develop
new
therapeut
option
highli
pathogen
coronaviru
infect
merscov
supplementari
materi
follow
avail
onlin
http
tabl
primer
probe
sequenc
use
rtqpcr
assay
tabl
antivir
activ
saracatinib
member
coronavirida
famili
figur
assay
valid
chemic
librari
screen
dot
repres
z
score
calcul
cell
control
viru
control
plate
brife
z
score
calcul
use
formula
repres
mean
standard
deviat
posit
neg
control
figur
saracatinib
inhibit
earli
stage
merscov
life
cycl
cell
treat
saracatinib
h
prior
viru
infect
pre
dmso
viru
control
vc
h
infect
co
h
postinfect
post
h
postinfect
post
h
pi
total
rna
isol
infect
lysat
collect
use
analys
intracellular
merscov
genom
rna
left
panel
mrna
upe
right
panel
rtqpcr
data
repres
mean
sd
two
independ
experi
perform
duplic
signific
differ
indic
p
p
p
p
figur
synergist
antivir
effect
saracatinib
gemcitabin
merscov
infect
cell
simultan
treat
dose
rang
ec
saracatinib
gemcitabin
combin
antivir
effect
assess
use
celltit
aq
ueou
one
solut
cell
prolifer
assay
data
repres
mean
sd
two
independ
experi
perform
duplic
